Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
This study is ongoing, but not recruiting participants.
Study NCT00458952 Information provided by Molecular Insight Pharmaceuticals, Inc.
First Received on April 9, 2007. Last Updated on August 1, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
More general conditions related to this trial
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Interventions listed in this trial
Ultratrace Iobenguane (MIBG) I 131
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Molecular Mechanisms of Pharmacological Action
Sponsors listed in this trial
Molecular Insight Pharmaceuticals, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers